Gilead Sciences, Inc.
- SEC CIK
- 0000882095
- Latest filing
- Aug 3, 2026
Holdings in Q2 2026
Holdings as of Jun 30, 2026, filed Aug 3, 2026. Long positions only; changes compare share counts with Q1 2026.
- Positions
- 5
- −1 vs. Q1 2026
- Portfolio value
- $1.65B
- −$469.0M (−22.1%) vs. Q1 2026
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| RCUSArcus Biosciences, Inc. | COM | 31,424,760 | $968.8M | 58.8% | 00.0% | Unchanged | History |
| LKFTLakefront Biotherapeutics NV | SPON ADR | 16,707,477 | $500.2M | 30.3% | 00.0% | Unchanged | History |
| ASMBAssembly Biosciences, Inc. | COM NEW | 4,977,089 | $136.8M | 8.3% | +471,698+10.5% | Added | History |
| KYTXKyverna Therapeutics, Inc. | COM | 4,126,119 | $36.8M | 2.2% | 00.0% | Unchanged | History |
| XLOXilio Therapeutics, Inc. | COM | 650,389 | $6.23M | 0.4% | 00.0% | Unchanged | History |
Sold out since Q1 2026 (1)
Positions held at the end of Q1 2026 that are gone from this filing.